Cargando…

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma

Pediatric patients with relapsed or refractory rhabdomyosarcoma (RMS) have dismal cure rates, and effective therapy is urgently needed. The oncogenic receptor tyrosine kinase fibroblast growth factor receptor 4 (FGFR4) is highly expressed in RMS and lowly expressed in healthy tissues. Here, we descr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Meijie, Wei, Jun S., Shivaprasad, Nityashree, Highfill, Steven L., Gryder, Berkley E., Milewski, David, Brown, G. Tom, Moses, Larry, Song, Hannah, Wu, Jerry T., Azorsa, Peter, Kumar, Jeetendra, Schneider, Dina, Chou, Hsien-Chao, Song, Young K., Rahmy, Abdelrahman, Masih, Katherine E., Kim, Yong Yean, Belyea, Brian, Linardic, Corinne M., Dropulic, Boro, Sullivan, Peter M., Sorensen, Poul H., Dimitrov, Dimiter S., Maris, John M., Mackall, Crystal L., Orentas, Rimas J., Cheuk, Adam T., Khan, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591056/ https://www.ncbi.nlm.nih.gov/pubmed/37774704 http://dx.doi.org/10.1016/j.xcrm.2023.101212

Ejemplares similares

Neutralization of murine myeloid-derived suppressor cells enhances the efficacy of a chimeric antigen receptor T-cells directed against pediatric solid tumors
por: Highfill, Steven L, et al.
Publicado: (2013)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
por: Schneider, Dina, et al.
Publicado: (2018)

Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
por: Hinson, Ashley R. P., et al.
Publicado: (2013)

Chondroitin sulfate proteoglycan 4 specific chimeric antigen receptor therapy for pediatric solid tumors
por: Tschernia, Nicholas, et al.
Publicado: (2014)

Embryonic Signaling Pathways and Rhabdomyosarcoma: Contributions to Cancer Development and Opportunities for Therapeutic Targeting
por: Belyea, Brian, et al.
Publicado: (2012)

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
por: Sullivan, Peter M., et al.
Publicado: (2022)

Immunotherapy Targets in Pediatric Cancer
por: Orentas, Rimas J., et al.
Publicado: (2012)

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
por: Schneider, Dina, et al.
Publicado: (2017)

Enhanced glycolytic metabolism is associated with exhaustion and poor antitumor efficacy in a xenograft model of chimeric antigen receptor T cell therapy for sarcoma
por: Long, Adrienne H, et al.
Publicado: (2013)

A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia
por: Masih, Katherine E., et al.
Publicado: (2023)

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

Corrigendum: A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
por: Bari, Rafijul, et al.
Publicado: (2019)

ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors
por: Orentas, Rimas J, et al.
Publicado: (2013)

Targeting high-risk pediatric solid tumors with CAR T cells directed against ALK (anaplastic lymphoma kinase, CD246)
por: Walker, Alec, et al.
Publicado: (2014)

Receptor Tyrosine Kinases as Therapeutic Targets in Rhabdomyosarcoma
por: Crose, Lisa E. S., et al.
Publicado: (2011)

Construction of a Large Size Human Immunoglobulin Heavy Chain Variable (VH) Domain Library, Isolation and Characterization of Novel Human Antibody VH Domains Targeting PD-L1 and CD22
por: Sun, Zehua, et al.
Publicado: (2022)

FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
por: Milewski, David, et al.
Publicado: (2021)

Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric Cancers
por: Orentas, Rimas J., et al.
Publicado: (2012)

Bioinformatic Description of Immunotherapy Targets for Pediatric T-Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison
por: Orentas, Rimas J., et al.
Publicado: (2014)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Chimeric engulfment receptors: A new cell therapy approach for SIV and HIV infection
por: Orentas, Rimas J.
Publicado: (2023)

Reference standards for accurate validation and optimization of assays that determine integrated lentiviral vector copy number in transduced cells
por: Paugh, Barbara S., et al.
Publicado: (2021)

Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma
por: Tenente, Inês M, et al.
Publicado: (2017)

Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma
por: Gryder, Berkley E., et al.
Publicado: (2019)

Advances in Lentiviral Vector-based Cell Therapy with Mesenchymal Stem Cells
por: Baranyi, Lajos, et al.
Publicado: (2012)

NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency
por: Marques, Joana G, et al.
Publicado: (2020)

Role of the YAP Oncoprotein in Priming Ras-Driven Rhabdomyosarcoma
por: Slemmons, Katherine K., et al.
Publicado: (2015)

Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma
por: Pomella, Silvia, et al.
Publicado: (2021)

BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma
por: Laubscher, Dominik, et al.
Publicado: (2021)

Epigenetic convergence in the rising tide of opioid overdose deaths
por: Hays, Cameron F., et al.
Publicado: (2022)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
por: Wu, Jerry T., et al.
Publicado: (2023)

In vivo killing of primary HIV-infected cells by peripheral-injected early memory–enriched anti-HIV duoCAR T cells
por: Anthony-Gonda, Kim, et al.
Publicado: (2022)

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma
por: Jackson, Zachary, et al.
Publicado: (2020)

Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)

Cell-Based Small-Molecule Compound Screen Identifies Fenretinide as Potential Therapeutic for Translocation-Positive Rhabdomyosarcoma
por: Herrero Martín, David, et al.
Publicado: (2013)

Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence
por: Li, Jenny J., et al.
Publicado: (2021)

Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line
por: Wang, Lingyan, et al.
Publicado: (2022)

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
por: Pacenta, Holly L., et al.
Publicado: (2021)

Towards a commercial process for the manufacture of genetically modified T cells for therapy
por: Kaiser, A D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a3537vsga4muh4c5st8jetnard